1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Ethacrynic Acid Tablets
Trade Name: Reomax
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as diuretic.

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethacrynic Acid</td>
<td>58-54-8</td>
<td>200-384-1</td>
<td>33</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Tablets
Signal Word: WARNING

Statement of Hazard: Harmful if swallowed.

Additional Hazard Information:
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver (based on components).

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include loss of appetite (anorexia), abdominal pain, changes in electrolytes, inability to swallow (dysphagia), nausea, vomiting, thirst, diarrhea. Clinical use has resulted in liver effects. Symptoms may include jaundice, liver function test abnormalities, and hepatitis. May cause adverse effects on the kidney. Other less common effects include allergic reaction, effects on hearing, vision. Drowsiness, fatigue, or headache are also possible.

EU Indication of danger: Harmful
EU Hazard Symbols:
4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash exposed area with soap and water, remove contaminated clothing and obtain medical assistance if irritation occurs. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride, and other chlorine-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

General Handling: Avoid generating airborne dust. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Starch

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total
= 5 mg/m³ TWA

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA
Australia TWA = 10 mg/m³ TWA

Magnesium stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals
Australia TWA = 10 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Tablets
Molecular Formula: Mixture
Color: Not applicable
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: None for the normal use of this material
Incompatible Materials: Incompatible with acids.

11. TOXICOLOGICAL INFORMATION

General Information: The information in this section describes the potential hazards of the individual ingredients and the formulation.

Product Level Toxicity Data
Repeated Dose Toxicity

Ingredients:

Acute Toxicity: (Species, Route, End Point, Dose)

Ethacrynic Acid

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Target Organ(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td></td>
<td>627 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Oral</td>
<td></td>
<td>1000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>IV</td>
<td>LD50</td>
<td>175 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>IP</td>
<td>LD50</td>
<td>43 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Intravenous</td>
<td>Maximally Symptomatic Dose</td>
<td>80 mg/kg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Lactose

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Target Organ(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td></td>
<td>&gt; 10 g/kg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Magnesium stearate

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Target Organ(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td></td>
<td>&gt; 2000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat</td>
<td>Inhalation</td>
<td>LC50</td>
<td>&gt; 2000 mg/m³</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Starch

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Target Organ(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>IP</td>
<td>LD50</td>
<td>6600 mg/kg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ethacrynic Acid

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Target Organ(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 Day(s)</td>
<td>Mouse</td>
<td>Oral</td>
<td>100 mg/kg/day</td>
<td>LOAEL</td>
<td>Liver</td>
</tr>
</tbody>
</table>

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ethacrynic Acid

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>No route specified</td>
<td>100 mg/kg</td>
<td>LOAEL</td>
<td>Not teratogenic</td>
</tr>
<tr>
<td>Fertility and Embryonic Development</td>
<td>Rat</td>
<td>No route specified</td>
<td>20 mg/kg/day</td>
<td>LOAEL</td>
<td>No effects at maximum dose</td>
</tr>
<tr>
<td>Fertility and Embryonic Development</td>
<td>Dog</td>
<td>No route specified</td>
<td>5 mg/kg/day</td>
<td>LOAEL</td>
<td>No effects at maximum dose</td>
</tr>
</tbody>
</table>

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ethacrynic Acid

<table>
<thead>
<tr>
<th></th>
<th>Species</th>
<th>Route</th>
<th>Dose (mg/kg/day)</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>79 Week(s)</td>
<td>Rat</td>
<td>No route specified</td>
<td>45 times human dose</td>
<td>LOAEL</td>
<td>Not carcinogenic</td>
</tr>
</tbody>
</table>

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Harmful
EU Risk Phrases: R22 - Harmful if swallowed.
EU Safety Phrases: S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:
WARNING
Harmful if swallowed.

Canada - WHMIS: Classifications

WHMIS hazard class: None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Ingredients:

Ethacrynic Acid
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS List: 200-384-1
16. OTHER INFORMATION

Reasons for Revision: Updated Section 10 - Stability and Reactivity.

Prepared by: Toxicology and Hazard Communication
              Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet